Search results for "quality-adjusted life years"

showing 10 items of 44 documents

Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2·5 air pollution, 1990–2019: an analysis of data from the G…

2022

Background: Experimental and epidemiological studies indicate an association between exposure to particulate matter (PM) air pollution and increased risk of type 2 diabetes. In view of the high and increasing prevalence of diabetes, we aimed to quantify the burden of type 2 diabetes attributable to PM2·5 originating from ambient and household air pollution.Methods: We systematically compiled all relevant cohort and case-control studies assessing the effect of exposure to household and ambient fine particulate matter (PM2·5) air pollution on type 2 diabetes incidence and mortality. We derived an exposure–response curve from the extracted relative risk estimates using the MR-BRT (meta-regress…

Contaminación del AireHealth (social science)Type II DiabetesType 2 diabetes deathsair pollutionand YLLs attributable to all PM2·5 air pollutionMedicine (miscellaneous)and change from 1990 to 2019DALYsburden of diseaseGlobal Burden of DiseaseCarga Global de EnfermedadesMELLITUSINFLAMMATIONand household PM2·5 pollution from solid fuels in seven GBD super-regions and globally in 2019Diabetes MellitusHumansBiologyASSOCIATIONSRISKINSULIN-RESISTANCEGBD 2019 Diabetes and Air Pollution CollaboratorsHealth PolicyMaterial ParticuladoPublic Health Environmental and Occupational HealthBayes TheoremLONG-TERM EXPOSUREHumanosYLDsChemistryDiabetes Mellitus Type 23121 General medicine internal medicine and other clinical medicineAños de Vida Ajustados por Calidad de Vidaambient PM2·5 pollutionParticulate MatterQuality-Adjusted Life YearsHuman medicineFINE PARTICULATE MATTERRAType II Diabetes; air pollution; burden of disease;The Lancet Planetary Health
researchProduct

Reproducible research practices, openness and transparency in health economic evaluations: study protocol for a cross-sectional comparative analysis

2020

INTRODUCTION: There has been a growing awareness of the need for rigorously and transparent reported health research, to ensure the reproducibility of studies by future researchers. Health economic evaluations, the comparative analysis of alternative interventions in terms of their costs and consequences, have been promoted as an important tool to inform decision-making. The objective of this study will be to investigate the extent to which articles of economic evaluations of healthcare interventions indexed in MEDLINE incorporate research practices that promote transparency, openness and reproducibility. METHODS AND ANALYSIS: This is the study protocol for a cross-sectional comparative ana…

Cost-Benefit Analysisdata sharingMEDLINEcost-effectiveness analysis data sharing methodology quality reporting reproducibility03 medical and health sciencesHealth Economics0302 clinical medicineHealth careProtocolOpenness to experienceHumansMedicine17011506030212 general & internal medicinereproducibilityProtocol (science)reportingMedical educationbusiness.industry030503 health policy & servicesCost-effectiveness analysiscost-effectiveness analysisRMethodologyReproducibility of ResultsmethodologyGeneral MedicineCost-effectiveness analysisTransparency (behavior)QualityReproducibility3. Good healthEconomics MedicalData sharingCross-Sectional StudiesReportingResearch DesignqualityEconomic evaluationMedicineData sharingQuality-Adjusted Life Years0305 other medical sciencebusiness
researchProduct

Global injury morbidity and mortality from 1990 to 2017 : results from the Global Burden of Disease Study 2017

2020

Publisher's version (útgefin grein)

DánarmeinFötlunDánartíðniLífslíkurLife expectancy1106 Human Movement and Sports Sciencesburden of diseaseGlobal HealthGlobal Burden of Disease0302 clinical medicineQuality-Adjusted Life YearGlobal healthMedicineLIFE EXPECTANCY030212 general & internal medicine1506POPULATIONCause of deathOriginal ResearchRISKeducation.field_of_studyGlobal disease burdensInjuriesSjúkdómarIncidence (epidemiology)IncidencePopulation healthBurden of diseaseGlobalglobal3142 Public health care science environmental and occupational health3. Good healthDescriptive epidemiologyLýðheilsaQuality-Adjusted Life YearsPublic HealthTERRITORIESdescriptive epidemiologyHumanPopulation195 COUNTRIESPopulation healthCause of deathburden of disease; descriptive epidemiology; global; Humans; Incidence; Life Expectancy; Morbidity; Quality-Adjusted Life Years; Global Burden of Disease; Global Health; Wounds and Injuries1117 Public Health and Health Services03 medical and health sciencesAGESYSTEMATIC ANALYSISHumansMortalityeducationDisabilitySEX-SPECIFIC MORTALITYbusiness.industryFaraldsfræðiDISABILITYPublic Health Environmental and Occupational HealthQuality-adjusted life yearYears of potential life lostÁverkar1701 PsychologyLife expectancyWounds and InjuriesHuman medicineMorbiditybusiness030217 neurology & neurosurgeryDemography
researchProduct

Carga global, regional y nacional de neurológicas. Desórdenes, 1990-2016: un análisis sistemático para el Global Estudio de la carga de enfermedad 20…

2019

Publisher´s version (útgefin grein).

DánarmeinMaleEpidemiologyDiseasesMalalties cerebralsGlobal Burden of DiseaseDisability Evaluation0302 clinical medicineCase fatality ratePsychologyKonurCause of deathAged 80 and overeducation.field_of_studyIncidenceMenTaugavísindiddc:3. Good healthSálfræðiWorld healthMuerteNeurologyGBD 2016 Neurology CollaboratorsBrain diseasesQuality-Adjusted Life YearsAlzheimer diseaseCarga global de enfermedadesNervous systemmedicine.medical_specialtyGlobal burden of diseasesLífsgæðiArticle03 medical and health sciencesHealth SciencesHumansWomeneducationTrastornos neurológicosVLAGAgedScience & Technology3112 NeurosciencesGlobal Burden of Diseases030104 developmental biologyYears of potential life lostΕπιστήμες ΥγείαςDementiaHuman medicineNeurosciences & NeurologyNeurology (clinical)Clinical Medicine1109 NeurosciencesNeurological disorders030217 neurology & neurosurgerydementiaRC0301 basic medicinePediatricsDánartíðniNutrition and Disease3124 Neurology and psychiatryDisease StudyTaugasjúkdómarRisk FactorsVoeding en ZiekteCause of DeathGlobal healthPrevalenceNeurological disorders; Global Burden of DiseasesCauses of deathPublic healthMortality rateMental DisordersAge FactorsPublic Health Global Health Social Medicine and EpidemiologyMiddle Agedneurologic diseaseDeathLýðheilsaFemaleLife Sciences & BiomedicineQuality of lifeAdultPopulationClinical NeurologySex FactorsmedicineLife ScienceDisability-adjusted life year:Medicine [Science]MortalityPsychiatryDisease burdenNeurology & Neurosurgeryburden of neurological disordersFaraldsfræðibusiness.industryKlinisk medicinCauses de la mort1103 Clinical SciencesFolkhälsovetenskap global hälsa socialmedicin och epidemiologiSocioeconomic FactorsKarlarglobal disease burdenNervous System DiseasesCause of death/trendsbusiness
researchProduct

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countr…

2015

Summary Background The Global Burden of Disease Study 2013 (GBD 2013) aims to bring together all available epidemiological data using a coherent measurement framework, standardised estimation methods, and transparent data sources to enable comparisons of health loss over time and across causes, age–sex groups, and countries. The GBD can be used to generate summary measures such as disability-adjusted life-years (DALYs) and healthy life expectancy (HALE) that make possible comparative assessments of broad epidemiological patterns across countries and time. These summary measures can also be used to quantify the component of variation in epidemiology that is related to sociodemographic develo…

GerontologyMaleCHANGING RELATIONNutrition and DiseaseMESH : Life ExpectancyMESH : AgedECONOMIC-DEVELOPMENTPoison controlMESH: Global HealthGlobal HealthSocioeconomic FactorCommunicable DiseaseMESH : Chronic DiseaseHealth TransitionVoeding en ZiekteQuality-Adjusted Life YearSELF-RATED HEALTHMESH : Socioeconomic FactorsMedicineMESH : FemaleMESH: Mortality Premature2. Zero hungerMESH: Agededucation.field_of_studyMESH: Middle AgedMortality rateMedicine (all)GBD2013 diseases[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieGeneral MedicineMiddle Aged3. Good healthMESH : Wounds and InjuriesEpidemiological transitionMESH: Quality-Adjusted Life YearsMESH: Communicable DiseasesNONCOMMUNICABLE DISEASESFemaleQuality-Adjusted Life YearsMESH: Life ExpectancyMESH: Health TransitionHumanMESH: Socioeconomic FactorsACUTE MYOCARDIAL-INFARCTIONMESH : MaleMORTALITY TRENDSPopulationMESH : Health TransitionCommunicable DiseasesArticleLife ExpectancyEUROPEAN-UNIONSDG 3 - Good Health and Well-beingGeneral & Internal MedicineSYSTEMATIC ANALYSISDisability-adjusted life yearHumansLife ScienceMESH : Middle AgedMortalityeducationPrematureMESH : Mortality PrematureVLAGAgedMESH: Humansbusiness.industryMortality PrematureMESH: Chronic DiseaseMESH : Communicable DiseasesWounds and InjurieMESH : HumansMESH : Quality-Adjusted Life YearsNon-communicable diseaseAged; Chronic Disease; Communicable Diseases; Female; Global Health; Humans; Male; Middle Aged; Mortality Premature; Quality-Adjusted Life Years; Socioeconomic Factors; Wounds and Injuries; Health Transition; Life Expectancy; Medicine (all)medicine.diseaseMESH: MaleLOW SOCIOECONOMIC-STATUSYears of potential life lostSocioeconomic Factors[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMESH: Wounds and InjuriesChronic DiseaseLife expectancyRISK-FACTORSMESH : Global HealthWounds and Injuries[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessMESH: FemaleDemographyLancet
researchProduct

The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017 : a systematic analysis for the Global Bu…

2020

Background\ud \ud Cirrhosis and other chronic liver diseases (collectively referred to as cirrhosis in this paper) are a major cause of morbidity and mortality globally, although the burden and underlying causes differ across locations and demographic groups. We report on results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 on the burden of cirrhosis and its trends since 1990, by cause, sex, and age, for 195 countries and territories.\ud \ud \ud \ud Methods\ud \ud We used data from vital registrations, vital registration samples, and verbal autopsies to estimate mortality. We modelled prevalence of total, compensated, and decompensated cirrhosis on the bas…

Liver CirrhosisMaleCirrhosisCost-Benefit AnalysisHEPATITIS-BGlobal Burden of DiseaseLiver diseaseDisability Evaluation0302 clinical medicineBurden Global Mortality CirrhosisNon-alcoholic Fatty Liver DiseaseRisk FactorsFIBROSISEurope EasternPOPULATIONAged 80 and overeducation.field_of_studySingaporeMortality rate1. No povertyGastroenterologyHepatitis CHepatitis BMiddle AgedHepatitis BHepatitis C3. Good healthPREVALENCE030220 oncology & carcinogenesisAsia Central030211 gastroenterology & hepatologyEgyptFemaleQuality-Adjusted Life YearsViral hepatitisLife Sciences & BiomedicineAdultEUROPEPopulationGBD 2017 Cirrhosis CollaboratorsArticle03 medical and health sciencesLIVER-DISEASEmedicineHumanseducationLiver Diseases AlcoholicAfrica South of the SaharaAgedScience & TechnologyHepatologyGastroenterology & Hepatologybusiness.industryMORTALITYDISABILITYDECOMPENSATIONmedicine.diseaseYears of potential life lostEarly DiagnosisSocioeconomic Factors3121 General medicine internal medicine and other clinical medicineINJURIESHuman medicinebusinessDemographyRCLancet gastroenterology & hepatology
researchProduct

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

2018

Background Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly…

Liver CirrhosisMaleTime FactorsCirrhosisKaplan-Meier Estimatelaw.inventionascites0302 clinical medicineHepatorenal syndromeRandomized controlled trialFurosemidelawAscitesClinical endpointParacentesisDiureticsalbumin decompensated cirrhosiMineralocorticoid Receptor AntagonistsSettore MED/12 - GastroenterologiaMedicine (all)Hazard ratioGeneral MedicineMiddle AgedSurvival RateCirrhosis030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyQuality-Adjusted Life Yearsmedicine.symptomHyponatremiamedicine.medical_specialty03 medical and health sciencesAlbuminsInternal medicinemedicineHumansSurvival ratealbuminAgedbusiness.industrycirrhosis; albumin; ascitesmedicine.diseaseClinical trialalbumin cirrhosis ascites liver decompensationQuality of LifeHyperkalemiabusinessEsophagus Varices Portal Hypertension Varicosis
researchProduct

Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?

2016

In Italy, the Italian Pharmaceutical Agency (AIFA) criteria used F3–F4 fibrosis stages as the threshold to prioritise the treatment with interferon (IFN)-free regimens, while in genotype 1 chronic hepatitis C (G1 CHC) patients with fibrosis of liver stage 2, an approach with pegylated interferon (PEG-IFN)-based triple therapy with simeprevir was suggested. The key clinical question is whether, in an era of financial constraints, the application of a universal IFN-free strategy in naive G1 CHC patients is feasible within a short time horizon. The aim of this study is to perform an economic analysis to estimate the cost-utility of the early innovative therapy in Italy for managing hepatitis C…

Liver CirrhosisSimeprevirmedicine.medical_specialtyCost-Benefit AnalysisPopulationAntiviral Agents03 medical and health sciencesIndirect costs0302 clinical medicineAntiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis C Chronic; Humans; Interferons; Italy; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Treatment Outcome; Pharmacology (medical)SimeprevirRibavirinmedicineHumansPharmacology (medical)030212 general & internal medicineChronicIntensive care medicineeducationReimbursementeducation.field_of_studyCost–benefit analysisbusiness.industryHealth services researchGeneral MedicineHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis CMarkov ChainsQuality-adjusted life yearTreatment OutcomeItalyDisease Progression030211 gastroenterology & hepatologyInterferonsQuality-Adjusted Life YearsbusinessMonte Carlo MethodClinical Drug Investigation
researchProduct

Adolescent transport and unintentional injuries: a systematic analysis using the Global Burden of Disease Study 2019

2022

Correction to Lancet Public Health 2022; 7: e657-69. Lancet Public Health. 2022 Dec;7(12):e992. doi: 10.1016/S2468-2667(22)00294-8. PMID: 36462522. Background: Globally, transport and unintentional injuries persist as leading preventable causes of mortality and morbidity for adolescents. We sought to report comprehensive trends in injury-related mortality and morbidity for adolescents aged 10-24 years during the past three decades. Methods: Using the Global Burden of Disease, Injuries, and Risk Factors 2019 Study, we analysed mortality and disability-adjusted life-years (DALYs) attributed to transport and unintentional injuries for adolescents in 204 countries. Burden is reported in absolut…

MaleAdolescentRJ101AdolescentsGlobal Burden of DiseaseLife ExpectancyRJ101 Child Health. Child health servicesSDG 3 - Good Health and Well-beingRA0421Risk FactorsRA0421 Public health. Hygiene. Preventive MedicineHumansMortalityChildrenInterventionsMCCUnintentional injuriesPreventionPublic Health Environmental and Occupational Health3rd-DASGBD 2019 Adolescent Transport and Unintentional Injuries Collaborators3142 Public health care science environmental and occupational healthAdolescent transportPreventable causesHealthFemaleQuality-Adjusted Life YearsInvestmentMorbidityAdolescent transport and unintentional injuries: a systematic analysis using the Global Burden of Disease Study 2019The Lancet Public Health
researchProduct

Global, regional, and national burden of stroke and its risk factors, 1990–2019 : a systematic analysis for the Global Burden of Disease Study 2019

2021

Background Regularly updated data on stroke and its pathological types, including data on their incidence, prevalence, mortality, disability, risk factors, and epidemiological trends, are important for evidence-based stroke care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) aims to provide a standardised and comprehensive measurement of these metrics at global, regional, and national levels. Methods We applied GBD 2019 analytical tools to calculate stroke incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and the population attributable fraction (PAF) of DALYs (with corresponding 95% uncertainty intervals [UIs]…

MaleAging030204 cardiovascular system & hematologyStroke dataGUIDELINES3124 Neurology and psychiatryBody Mass IndexGlobal Burden of Disease0302 clinical medicineRA0421Risk FactorsEpidemiologyStrokesYOUNG-ADULTSPrevalence80 and overAetiology610 Medicine & healthStrokePOPULATION1103 Clinical Sciences 1109 NeurosciencesCause of deathAged 80 and overeducation.field_of_studyMortality rateIncidence (epidemiology)Incidence1. No povertyArticlesHälsovetenskaperMiddle AgedStroke typesddc:3. Good healthStrokeISCHEMIC-STROKEIncomeFemaleQuality-Adjusted Life YearsLife Sciences & BiomedicineAdultmedicine.medical_specialtyGBDPopulationClinical SciencesClinical Neurology610 Medicine & health03 medical and health sciencesClinical ResearchMIDDLE-INCOME COUNTRIESHealth SciencesmedicineHumansRisk factoreducationGBD 2019 Stroke CollaboratorsCerebral HemorrhageAgedIschemic StrokeGlobal burdenScience & TechnologyNeurology & NeurosurgeryHYPERTENSIONbusiness.industryMORTALITYPrevention3112 NeurosciencesNeurosciences1103 Clinical SciencesSERVICESSubarachnoid Hemorrhagemedicine.diseasePREVENTIONBrain DisordersGood Health and Well BeingAttributable riskHuman medicineNeurology (clinical)Neurosciences & Neurologybusiness1109 Neurosciences030217 neurology & neurosurgeryDemography2.4 Surveillance and distributionRC
researchProduct